Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score in young women with estrogen receptor-positive early breast cancer.
Sella T, Gelber S, Poorvu P, Kim H, Guzman Arocho Y, Collins L, Ruddy K, Tamimi R, Peppercorn J, Schapira L, Borges V, Come S, Warner E, Snow C, Jakubowski D, Russell C, Winer E, Rosenberg S, Partridge A. Response to neoadjuvant chemotherapy and the 21-gene breast recurrence score in young women with estrogen receptor-positive early breast cancer. Journal Of Clinical Oncology 2020, 38: 514-514. DOI: 10.1200/jco.2020.38.15_suppl.514.Peer-Reviewed Original ResearchPathologic complete responseBreast Recurrence ScoreNeoadjuvant chemotherapyBreast cancerRecurrence scoreBreast Cancer StudyYoung womenHER2- BCEstrogen receptor-positive early breast cancerHER-2 negative breast cancerReceptor-positive early breast cancerYoung Women's Breast Cancer StudyNeoadjuvant endocrine therapyResidual invasive tumorEarly breast cancerPost-menopausal womenNegative breast cancerHigh gradeLogistic regression modelingAdjuvant chemotherapyDuctal histologyPgR negativityEndocrine therapyNeoadjuvant therapyProspective cohort